Sodium polystyrene sulphonate (SPS) has been widely used for hyperkalemia management in chronic kidney disease (CKD). However, data on its safety are scarce and ambiguous. A retrospective cohort study based on the nationwide Swedish Renal Registry examined patterns of use and adverse events associated to SPS initiation during follow-up. 3690 patients initiated SPS during follow-up, […]
https://www.era-edta.org/en/wp-content/uploads/2020/10/m_gfz150f2_1200.png3931200ERA-EDTAERA-EDTA2020-10-19 10:55:552020-10-19 10:55:55The risks of gastrointestinal adverse events with initiation of sodium polystyrene sulphonate
The increase in kidney transplant activity in Spain in recent years has relied on acceptance of organs from increasingly older donors and donation after circulatory death (cDCD). This has triggered Concerns about outcomes achieved with these elderly cDCD. A single-ceter retrospective study evaluated 87 cDCD-kidney transplant recepients (KTrs), 46 from donors ≥65 years of age and […]
https://www.era-edta.org/en/wp-content/uploads/2020/10/m_sfaa114f1.png4301020ERA-EDTAERA-EDTA2020-10-16 11:40:032020-10-16 11:40:03Are all donated kidneys the same?
NaPi-IIb, a type II sodium-dependent phosphate transporter, is considered a dominant transporter in rodents for phosphate absorption in the small intestine. However, the regulation of its expression in chronic kidney disease (CKD) is still ambiguous. A recent study measured protein expression level of NaPi-Iib in CKD-rats by mass spectrometry to evaluate the extent of phosphate […]
https://www.era-edta.org/en/wp-content/uploads/2020/10/m_gfaa156f3.png241520ERA-EDTAERA-EDTA2020-10-14 10:02:322020-10-14 10:02:32Which phosphate transporters should be targeted to reduce hyperphosphatemia?
Antidiuertic hormone (ADH), commonly known for regulating body’s water balance, has recently been linked to osteoporosis during ageing and microgravity/bed rest. This prompted a research on the possible role od ADH in modulating renal calcium excretion. Data for 12 patients with central diabetes insipidus (CDI) and measured 24-h urinary excretion levels of calcium have been […]
https://www.era-edta.org/en/wp-content/uploads/2020/10/m_sfaa134f1.png150520ERA-EDTAERA-EDTA2020-10-12 16:31:012020-10-12 16:31:01Does ADH modulate renal calcium excretion in patients with CDI and hypercalciuria?
Tolvaptan is an oral aquaretic agent which selectively antagonizes arginine vasopressin V2 receptors and increases free water excretion. A total of 124 hemodialyzed patients with preserved diuresis were recruited in a randomized, double-blind, placebo-controlled, Phase 2 trial to assess tolvaptan efficacy and safety. They were randomized to receive oral tolvaptan 15 mg/day or 30 mg/day, or placebo […]
Rituximab (RTX) is an effective remission-induction and maintenance treatment for patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The major challenge of patient care is the early detection of relapse to prevent organ damage and improve survival in these individuals. A recently published single-center cohort study assessed serial ANCA, CD19+ B-cell status and relapse rate […]
Acute kidney injury (AKI) may occur in 4-23% of patients with COVID-19. Those who require renal replacement therapy have mainly been treated with extracorporeal dialysis. However, peritoneal dialysis (PD) may also be considered as a valuable treatment option in such cases when there is a capacity limit or availability constraint of equipment and supplies for […]
https://www.era-edta.org/en/wp-content/uploads/2020/08/Def.-Logo-CKJ_rett.png358600ERA-EDTAERA-EDTA2020-08-17 09:47:292020-08-17 09:50:29Acute PD in the treatment of COVID-19-related AKI
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the exponential and unlimited enlargement of the total kidney volume (TKV) associated with a decrease in renal function. In the prospective, placebo-controlled tolvaptan efficacy and safety in the management of ADPKD and its outcomes (TEMPO) 3:4 trial a mixed-model repeated-measures analysis was applied to assess a […]
https://www.era-edta.org/en/wp-content/uploads/2020/08/gr1.jpg380509ERA-EDTAERA-EDTA2020-08-06 09:16:202020-08-06 09:16:20Easy estimation of renal growth rate in ADPKD
Several studies report direct infection of different types of kidney cells by SARS-CoV-2 detected by transmission electron microscopy (TEM) both on post-mortem analysis and kidney biopsy specimens. However, these studies did not include detection of viral RNA or other methods for viral detection of kidney specimens and thus it is unclear whether the observed particles […]
https://www.era-edta.org/en/wp-content/uploads/2020/07/covid19.jpg520600ERA-EDTAERA-EDTA2020-07-27 12:28:032020-07-27 12:28:03Are those really SARS-CoV-2 virions in the kidney?
A Clinical Trial of IntensiVE (ACTIVE) Dialysis randomized 200 participants to extended hours (≥24 hours/week) or standard (≤18 hours/week) dialysis for 12 months to determine whether extended hours result in improved survival. After completing the 12-month study period participants could change their dialysis regimen, but continued a pre-specified observational follow-up for a further 4 years. […]
https://www.era-edta.org/en/wp-content/uploads/2020/07/shutterstock_eudial_rid.png536698ERA-EDTAERA-EDTA2020-07-27 12:19:262020-07-27 12:19:26Is longer dialysis necessarily better? The results of the ACTIVE Trial
The risks of gastrointestinal adverse events with initiation of sodium polystyrene sulphonate
News, News-HomeSodium polystyrene sulphonate (SPS) has been widely used for hyperkalemia management in chronic kidney disease (CKD). However, data on its safety are scarce and ambiguous. A retrospective cohort study based on the nationwide Swedish Renal Registry examined patterns of use and adverse events associated to SPS initiation during follow-up. 3690 patients initiated SPS during follow-up, […]
Are all donated kidneys the same?
News, News-HomeThe increase in kidney transplant activity in Spain in recent years has relied on acceptance of organs from increasingly older donors and donation after circulatory death (cDCD). This has triggered Concerns about outcomes achieved with these elderly cDCD. A single-ceter retrospective study evaluated 87 cDCD-kidney transplant recepients (KTrs), 46 from donors ≥65 years of age and […]
Which phosphate transporters should be targeted to reduce hyperphosphatemia?
News, News-HomeNaPi-IIb, a type II sodium-dependent phosphate transporter, is considered a dominant transporter in rodents for phosphate absorption in the small intestine. However, the regulation of its expression in chronic kidney disease (CKD) is still ambiguous. A recent study measured protein expression level of NaPi-Iib in CKD-rats by mass spectrometry to evaluate the extent of phosphate […]
Does ADH modulate renal calcium excretion in patients with CDI and hypercalciuria?
News, News-HomeAntidiuertic hormone (ADH), commonly known for regulating body’s water balance, has recently been linked to osteoporosis during ageing and microgravity/bed rest. This prompted a research on the possible role od ADH in modulating renal calcium excretion. Data for 12 patients with central diabetes insipidus (CDI) and measured 24-h urinary excretion levels of calcium have been […]
Tolvaptan maintains diuretic action in hemodialysis patients
News, News-HomeTolvaptan is an oral aquaretic agent which selectively antagonizes arginine vasopressin V2 receptors and increases free water excretion. A total of 124 hemodialyzed patients with preserved diuresis were recruited in a randomized, double-blind, placebo-controlled, Phase 2 trial to assess tolvaptan efficacy and safety. They were randomized to receive oral tolvaptan 15 mg/day or 30 mg/day, or placebo […]
PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab treatment
News, News-HomeRituximab (RTX) is an effective remission-induction and maintenance treatment for patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The major challenge of patient care is the early detection of relapse to prevent organ damage and improve survival in these individuals. A recently published single-center cohort study assessed serial ANCA, CD19+ B-cell status and relapse rate […]
Acute PD in the treatment of COVID-19-related AKI
News, News-HomeAcute kidney injury (AKI) may occur in 4-23% of patients with COVID-19. Those who require renal replacement therapy have mainly been treated with extracorporeal dialysis. However, peritoneal dialysis (PD) may also be considered as a valuable treatment option in such cases when there is a capacity limit or availability constraint of equipment and supplies for […]
Easy estimation of renal growth rate in ADPKD
News, News-HomeAutosomal dominant polycystic kidney disease (ADPKD) is characterized by the exponential and unlimited enlargement of the total kidney volume (TKV) associated with a decrease in renal function. In the prospective, placebo-controlled tolvaptan efficacy and safety in the management of ADPKD and its outcomes (TEMPO) 3:4 trial a mixed-model repeated-measures analysis was applied to assess a […]
Are those really SARS-CoV-2 virions in the kidney?
News, News-HomeSeveral studies report direct infection of different types of kidney cells by SARS-CoV-2 detected by transmission electron microscopy (TEM) both on post-mortem analysis and kidney biopsy specimens. However, these studies did not include detection of viral RNA or other methods for viral detection of kidney specimens and thus it is unclear whether the observed particles […]
Is longer dialysis necessarily better? The results of the ACTIVE Trial
News, News-HomeA Clinical Trial of IntensiVE (ACTIVE) Dialysis randomized 200 participants to extended hours (≥24 hours/week) or standard (≤18 hours/week) dialysis for 12 months to determine whether extended hours result in improved survival. After completing the 12-month study period participants could change their dialysis regimen, but continued a pre-specified observational follow-up for a further 4 years. […]